NSF I-Corps: Wide Working Range Test for the Diagnosis of Immune Mediated Disease in Animals

NSF I-Corps：用于诊断动物免疫介导疾病的宽工作范围测试

• 批准号: 1844572
• 负责人: Yuriy Markushin
• 金额: $ 5万
• 依托单位: Delaware State University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-10-01 至 2023-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1844572&HistoricalAwards=false
• 关键词: NSF; Corps; Wide; Working; Range

The broader impact/commercial potential of this I-Corps project will be accomplished through helping more than 85 million US pet owners and their pets, as owning a companion animal is associated with improved well-being. The provisional-patent-protected innovation, a single-test immunoassay for pet disease diagnosis, is expected to lead to significant outcomes in the animal healthcare commercial market, with an option of expanding to other markets.This project is based on technology that combines in a single test (such as a paper strip test) the high sensitivity, selectivity and wide working range of the particle immunoassay for diagnosing pets' diseases at various stages. The unique feature of our test is high sensitivity with the incorporated protection against false-negative analytical bias caused by the high dose effect, which is important for the diagnostic accuracy of late- and early-stage disease. The selectivity of the test has been demonstrated to detect about 0.01 Units per milliliter of ovarian cancer biomarker 125 in human blood plasma, with near single-molecule assay selectivity. In the proof-of-concept experiment, the proposed approach was modified based on the heterogeneous-media encapsulation of gold nanoparticles modified with biotin and iron oxide microparticles modified with streptavidin. This test offers significant competitive advantages over existing technologies: it can be used for early- and late-stages of disease; manufacturing and operational costs are low, based on a cheap point-of-care application; and it offers the possibility of detecting multiple modalities of disease in one test.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个I-Corps项目的更广泛的影响/商业潜力将通过帮助超过8500万美国宠物主人和他们的宠物来实现，因为拥有伴侣动物与改善福祉有关。这项受临时专利保护的创新技术是一种用于宠物疾病诊断的单次检测免疫分析技术，预计将在动物医疗保健商业市场取得重大成果，并可扩展到其他市场。（例如试纸条测试）高灵敏度，选择性强，工作范围广，可用于诊断不同阶段的宠物疾病。我们的测试的独特之处在于高灵敏度，并结合了对高剂量效应引起的假阴性分析偏倚的保护，这对于晚期和早期疾病的诊断准确性非常重要。已证明该测试的选择性可检测人血浆中约0.01单位/毫升的卵巢癌生物标志物125，具有接近单分子测定的选择性。在概念验证实验中，基于生物素修饰的金纳米颗粒和链霉亲和素修饰的氧化铁微粒的异质介质封装，对所提出的方法进行了修改。与现有技术相比，该检测具有显著的竞争优势：可用于疾病的早期和晚期;基于廉价的护理点应用，制造和运营成本低;该奖项反映了NSF的法定使命，并被认为值得通过使用基金会的智力价值进行评估来支持和更广泛的影响审查标准。